Clough Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Clough Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-715	Closed	-$509K	–	135
2024 Q4	$509K	Hold	715	–	–	0.06%	103
2024 Q3	$752K	Hold	715	–	–	0.08%	106
2024 Q2	$751K	Hold	715	–	–	0.08%	98
2024 Q1	$688K	Hold	715	–	–	0.08%	89
2023 Q4	$628K	Buy	715 +140	+24%	+$115K	0.07%	128
2023 Q3	$473K	Sell	575 -7,230	-93%	-$5.68M	0.05%	135
2023 Q2	$5.61M	Buy	+7,805	New	+$6.02M	0.56%	57
2022 Q1	–	Sell	-26,040	Closed	-$16.4M	–	139
2021 Q4	$16.4M	Sell	26,040 -6,945	-21%	-$4.27M	1.1%	30
2021 Q3	$20M	Sell	32,985 -22,535	-41%	-$14M	1.21%	29
2021 Q2	$31M	Buy	+55,520	New	+$28.1M	1.69%	16
2021 Q1	–	Sell	-8,384	Closed	-$4.05M	–	168
2020 Q4	$4.05M	Sell	8,384 -14,908	-64%	-$8.05M	0.29%	77
2020 Q3	$13M	Sell	23,292 -5,823	-20%	-$3.53M	0.94%	39
2020 Q2	$18.2M	Sell	29,115 -8,120	-22%	-$4.61M	1.78%	16
2020 Q1	$18.2M	Buy	37,235 +10,255	+38%	+$4.23M	1.81%	16
2019 Q4	$10.1M	Buy	+26,980	New	+$9.08M	0.86%	44

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Clough Capital Partners's REGN Position: Q1 2025 in Review

Clough Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 715 shares — an estimated $509K sold.

Clough Capital Partners first reported a position in REGN in Q4 2019 and held it in 15 quarters. The position peaked at $31M in Q2 2021. 1,291 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Clough Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Clough Capital Partners sold 715 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $509K.
Clough Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 15 quarters.
Clough Capital Partners's Regeneron Pharmaceuticals position peaked at $31M in Q2 2021.
1,291 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Clough Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.